Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation

Mimi Wang1, Rongrong Yao2 and Yanhong Wang1

1 Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
2 Huashan Hospital, Fudan University, Shanghai, China

Keywords
epithelial-mesenchymal transition; ERK signaling; hepatocellular carcinoma; interleukin-13 receptor alpha 2

Correspondence
Y. Wang, Liver Cancer Institute, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China
E-mail: wangyanhong6866@163.com

(Received 25 April 2019, revised 16 September 2019, accepted 4 November 2019)
doi:10.1002/2211-5463.12774

Lack of insight into the mechanisms underlying hepatocellular carcinoma (HCC) metastasis has hindered the development of curative treatments. Overexpression of interleukin-13 receptor alpha 2 (IL13RA2) has been reported to contribute to invasion and metastasis in several tumors. However, the role of IL13RA2 in HCC remains to be characterized. In this study, we identified that low expression of IL13RA2 is associated with poor survival of patients with HCC, and demonstrated that IL13RA2 knockdown endows HCC cells with invasive potential. Mechanistically, silencing of IL13RA2 promotes partial epithelial-mesenchymal transition via increasing extracellular signal-regulated kinase phosphorylation in HCC. Collectively, our results suggest that IL13RA2 may have potential as a prognostic biomarker for HCC.

Up to 2018, hepatocellular carcinoma (HCC) was evaluated as the sixth most common cancer in the world and the fourth leading cause of cancer death [1]. With the advancement of diagnostics and the popularity of surveillance programs, the proportion of early-stage HCC in the diagnosis of HCC has increased significantly. In developed countries, 40% of patients with HCC could be diagnosed as early stage, for which curative treatment is available [2–4]. Nonetheless, the metastasis and recurrence of HCC are a major obstacle to improving overall survival (OS) and quality of life of patients. However, the mechanisms underlying the metastasis of HCC remain obscure, leading to limited metastasis-targeted therapeutics.

Metastasis is a dynamic procedure that includes invasion to surrounding matrix, intravasation, survival and transit in the circulating system, extravasation, seeding in distant organs and clonal proliferation to form a metastasis niche. Genetic and epigenetic changes that form networks or pathways are involved in the whole metastatic process. Therefore, understanding deregulated gene expression that drives metastasis initiation is of great importance, both for prognosis and for therapeutic targets.

Interleukin-13 receptor alpha 2 (IL13RA2), 43 kDa, is one of the receptors for IL-13 [5]. IL-13 is a Th2 helper molecule involved in inflammation, wound healing, allergy and immune regulation. Moreover, IL-13 plays a key role in many pathological processes, such as asthma, pulmonary fibrosis and ulcerative colitis [6–8]. The classic pathway for IL-13 activation is JAK/STAT6 via binding to receptor interleukin-13 receptor alpha 1, not IL13RA2. IL13RA2 had once been deemed as a decoy receptor [9–11], but recent studies have demonstrated that IL-13

Abbreviations
CCK-8, Cell Counting Kit-8; DMEM, Dulbecco’s modified Eagle’s medium; EGFRvIII, epidermal growth factor receptor variant III; EMT, epithelial-mesenchymal transition; ERK, extracellular signal-regulated kinase; GEO, Gene Expression Omnibus; HCC, hepatocellular carcinoma; IL13RA2, interleukin-13 receptor alpha 2; OS, overall survival; SD, standard deviation; TCGA, The Cancer Genome Atlas.
could act on IL13RA2 to activate extracellular signal-regulated kinase (ERK)/activator protein 1 [12,13] and Scr/phosphoinositide 3-kinase/Akt/mammalian target of rapamycin [14] downstream pathways. Up to now, we concluded that IL13RA2 has two forms: transmembrane form and extracellular soluble form [15–17]. The former is involved in signaling of ligands such as IL-13, as well as binding to other membrane receptors, such as epidermal growth factor receptor variant III (EGFRvIII) [18], to form different functional subunits. As a decoy receptor, soluble IL13RA2 appears to inhibit the effects of IL13 [7,15]. Taken together, the functions of these two isoforms could be antagonistic.

In several solid tumors, studies reported that IL13RA2 could predict poorer survival, such as glioblastoma [18], breast cancer [19], colorectal cancer [20] and pancreatic cancer [21]. In addition, these studies revealed that overexpression of IL13RA2 could confer invasive and metastatic ability on tumor cells. However, the roles of IL13RA2 on HCC are poorly understood. In this study, we aimed to detect the expression level of IL13RA2 on HCC and to evaluate its contribution to metastasis.

Materials and methods

Cell culture

The human HCC cell lines—Hep G2, PLC/PRF/5, SMMC7721, Huh7, MHCC97L, MHCC97H, HCCLM3 cell line and the hepatocyte cell line L02—were all obtained from the Liver Cancer Institute at Fudan University in Shanghai, China. Among them, MHCC97L, MHCC97H and HCCLM3 are all of high metastatic potential, deriving from parent MHCC97 cells; MHCC97H has a relatively low metastatic potential, whereas MHCC97H and HCCLM3 have relatively high metastatic potential. All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS (CellSera, Rutherford, NSW, Australia) in an atmosphere of 5% CO₂ at 37 °C.

Lentivirus short hairpin RNA transfection

Short hairpin RNA was used to construct recombinant lentivirus. The sequence to target human IL13R A2 was as follows: 5'-UCAGGAUUGGAUUGCGUA-3'; and the vector was PGMLV-hU6-MCS-CMV-ZsGreen1-PGK-Puro-WPRE. The whole products were designed by Genomeditech Company (Shanghai, China), and HCC cell lines were transfected with lentivirus following the manufacturer’s protocol.

Real-time quantitative PCR analysis

Total RNA was extracted from cells using TRizol Reagent (Sigma, Saint Louis, MO, USA), and the cDNA was synthesized with PrimeScript RT reagent kit with gDNA eraser (Takara, Kusatsu, Japan). Quantitative real-time PCR was performed on CFX96 Touch (Bio-Rad Laboratories, Hercules, CA, USA) using SYBR premix ex Taq (ThiRNAseH Plus) (Takara). The specific primer pairs used for human IL13RA2 are as follows: forward 5'-ACCTGGCATAGGTGTAATCTT-3' and reverse 5'-CCAAATAGGGAAATCTGATCCT-3'. Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was used as endogenous control.

Western blot analysis

Cells were lysed in radioimmunoprecipitation assay buffer with 1% PMSF and 10% phosphatase inhibitor (Beyotime Biotechnology, Shanghai, China), the protein concentrations were measured using the bicinchoninic acid method (Beyotime Biotechnology), and 20 μg protein per sample was separated in 10% SDS/PAGE using electrophoresis and transferred to polyvinylidene fluoride membranes (Milipore, Billerica, MA, USA). After 2 h of blocking with a TBST buffer (Sangon Biotech, Shanghai, China), containing 5% fat-free milk at room temperature, the membranes were incubated with primary antibodies at 4 °C overnight. The next day, the membranes were washed three times with 1× TBST and then incubated with corresponding secondary antibodies for 1 h at room temperature. Finally, the blots were detected by Immobilon™ Western Chemiluminescent HRP Substrate (ECL; Millipore). The primary antibodies we used in the research are listed as follows: IL13 Rα2 (#AF1146; R&D Systems, Minneapolis, MN, USA), E-cadherin (#ab40772; Abcam, Cambridge, MA, USA), N-cadherin (#ab76011; Abcam), Vimentin (#ab92547; Abcam), Erk 1/2 (#9102; Cell Signaling Technology (CST), Danvers, MA, USA), phospho (p)-Erk 1/2 (#4370; CST) and GAPDH (#AF0006; Beyotime Biotechnology).

Flow cytometry analysis of apoptosis

Cells were collected, resuspended into 1 × 10⁶/mL in 200 μL 1× binding buffer and added to 5 μL Annexin V Recom APC and 5 μL 7-aminoactinomycin D (BD Pharmingen, San Diego, CA, USA). After incubation at room temperature for 15 min away from light, cells were added to 300 μL 1× binding buffer to be analyzed in a flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA, USA).

Cell proliferation assay

Four thousand cells per well were seeded into a 96-well plate. Cell proliferation assay was performed using Cell Counting Kit-8 (CCK-8; Beyotime Biotechnology) 24, 48, 72 and 96 h after cell seeding. The absorbance was detected at a wavelength of 450 nm (A450 nm) after 10 μL mixture reagent (10 μL CCK-8 and 100 μL DMEM) was added into each well and incubated at 37°C for 1 h.

230
Wound-healing assay

We used a 200-µL plastic pipette tip to make a wound in a six-well plate with a cell density of 90% confluence. Subsequently, the cell was washed gently twice with PBS and cultured with DMEM containing 5% FBS. Scratches were photographed at 0, 24, 48 and 72 h after wounding. We used IMAGEJ (National Institutes of Health, Bethesda, MD, USA) to analyze the area of wound healing in different time points: Wound-healing percentage = (scratch area in 0 h − scratch area in 48 or 72 h)/scratch area in 0 h.

Cell migration assays

A total of 1 × 10⁵ cells with 100 μL FBS-free DMEM were plated in the upper chamber (8.0-µm pore size; Corning Incorporated, Corning, NY, USA), and 600 μL 10% FBS DMEM was added into the lower chamber. After 72 h, migrating cells were fixed by 4% paraformaldehyde (Beyotime Biotechnology), stained with crystal violet (Beyotime Biotechnology) for 20 min and photographed in a high-magnification field of vision.

Statistical analysis

Kaplan–Meier survival analysis in Kaplan–Meier Plotter used the log rank test. Gene Expression Profiling Interactive Analysis (http://geopia.cancer-pku.cn/) [22] was used to determine whether one gene is expressed differently between HCC and normal hepatic tissue in The Cancer Genome Atlas (TCGA) database, where the P value was calculated using one-way ANOVA; the cutoff of |log₂FC| (where FC represents fold change) and P value were 1 and 0.05, respectively. Continuous variables were expressed as the mean ± standard deviation (SD) and analyzed using two-tailed Student’s t-test; P < 0.05 was considered significantly different.

Results

Overexpression of IL13RA2 in HCC predicts good long-term survival

To identify the clinical significance of IL13RA2 in HCC, we performed a Kaplan–Meier survival analysis in Kaplan–Meier Plotter (http://kmplot.com/analysis/index.php?p=service&cancer=liver_rnas eq), which integrated three independent transcriptomic datasets: TCGA, Gene Expression Omnibus (GEO): GSE20017 and GEO: GSE9843 [23]. OS available data included 364 patients. OS for patients with low IL13RA2 expression (115 patients) was significantly poorer than that for patients with high IL13RA2 expression (249 patients) (Fig. 1). Intriguingly, the clinical impact of IL13RA2 in HCC is opposite to other solid tumors.

The expression of IL13RA2 in HCC

To determine IL13RA2 expression in human HCC and cell lines, we performed TCGA database analysis, which included 50 normal hepatic tissue samples and 369 tumor samples. TCGA database analysis revealed that the expression of IL13RA2 was higher in normal hepatic tissue compared with its expression in tumor (Fig. 2A). Then we validated IL13RA2 expression in different human HCC cell lines and normal hepatocyte (L02) via quantitative RT-PCR and western blot. Compared with most HCC cell lines (Hep G2, PLC/PRF/5, SMMC7721, Huh7), the mRNA expression of IL13RA2 was slightly higher in hepatocyte L02 (Fig. 2B,C), which was analogous to TCGA analysis result. Intriguingly, IL13RA2 was overexpressed significantly in MHCC97 cell lines by mRNA level and highly expressed in MHCC97H and HCCLM3 cells, but not MHCC97L, by protein level (Fig. 2B,C).

IL13RA2 silencing promotes cell proliferation and migration, but inhibits cell apoptosis

To characterize the role of IL13RA2 in MHCC97H and HCCLM3 cells, we knocked down IL13RA2 with stable lentivirus transfection of short hairpin RNA. As
shown in Fig. 3A, IL13RA2 knockdown conferred enhanced cell proliferation in HCCLM3, whereas the change was not evident in MHCC97H cells. In addition, IL13RA2 silencing in both MHCC97H and HCCLM3 caused lower cell apoptosis rate (Fig. 3B). To determine the effect of IL13RA2 on cell migration, we used wound-healing assays and Transwell cell migration assays. The results confirmed that IL13RA2 knockdown increased cell migration ability in HCC cells (Fig. 3C-D).

**IL13RA2 silencing enhances epithelial-mesenchymal transition through the ERK pathway**

To explore the potential mechanism of IL13RA2 function in HCC, we detected the level of E-cadherin, N-cadherin and Vimentin in IL13RA2 knockdown HCC cells comparable with the control group. As displayed in Fig. 4A, in IL13RA2 knockdown MHCC97H cells, E-cadherin was down-regulated, whereas N-cadherin and Vimentin were up-regulated significantly. In HCCLM3 cells, IL13RA2 silencing up-regulated the expression of N-cadherin and Vimentin, with no obvious change in E-cadherin. These results demonstrated that IL13RA2 knockdown HCC cells underwent different types of epithelial-mesenchymal transition (EMT) program. Next, we studied the downstream pathway involved in EMT via western blot and found that the increase in p-Erk expression was significant for both MHCC97H and HCCLM3 cells (Fig. 4B). Collectively, IL13RA2 silencing could induce intermediate hybrid EMT states through ERK activation in different HCC cells.

**Discussion**

It is well documented that IL13RA2-targeted therapies have gained considerable effect in tumor treatment, such as IL13RA2 monoclonal antibody [24] and IL13R-specific chimeric antigen receptor-modified T cells [25,26] for glioblastoma multiforme. Hence, at the very start, we intended to evaluate the role of IL13RA2 in HCC and whether these IL13RA2-targeted interventions are applicable to HCC.

In contrast with existing research results in other tumors, our study found that low expression level of IL13RA2 in HCC predicted a shorter survival and identified IL13RA2 as being low expressed in patients with HCC through TCGA database analysis. However, human HCC cell lines MHCC97H and HCCLM3 expressed high levels of IL13RA2 specifically, characterizing the heterogeneity in the expression of IL13RA2 on HCC. Intriguingly, the MHCC97L cell line also contained a higher level IL13RA2 mRNA, but the amount of protein expression was relatively low. As we know, the mRNA abundance of a particular gene does not
necessarily have a linear relationship with its translation product protein expression, mainly because there are many levels of regulation of gene expression, such as the regulation of transcriptional level, as well as post-transcriptional regulation and translation and post-translational regulation. Therefore, we speculated that in MHCC97L, IL13RA2 mRNA might experience degradation or interference, which could be a novel target to elevate IL13RA2 protein expression level to suppress HCC metastasis.

Our results showed that IL13RA2 could contribute to cell apoptosis and inhibiting cell proliferation and migration without addition of IL-13. This phenomenon has also appeared in other reports [18,20]. One illustration is that serum may contain sufficient IL-13 or other ligands. Moreover, we found that IL13RA2 silencing could promote cell proliferation of HCCLM3, but not of MHCC97H. As we mentioned earlier, not only can IL13RA2 respond to IL-13 alone, but it can also bind with other membrane proteins to play unique functions. For example, in glioblastoma multiforme [18], no significant change was observed in cell proliferation in IL13RA2 loss tumor cells with the absence of mutant EGFR (EGFRvIII). In contrast, in

![Image](https://example.com/image1.png)

Fig. 3. IL13RA2 silencing enhances cell proliferation and migration, but inhibits cell apoptosis. (A) CCK-8 assay for cell proliferation of MHCC97H-shIL13RA2 cells and HCCLM3-shIL13RA2 cells compared with their vector control. IL13RA2 knockdown increased cell proliferation of HCCLM3, but not of MHCC97H. (B) Flow cytometry analysis of apoptosis of MHCC97H-shIL13RA2 cells and HCCLM3-shIL13RA2 cells compared with their vector control. IL13RA2 knockdown decreased the total and early apoptosis rates of MHCC97H and HCCLM3 cells. (C, D) Wound-healing assays (original magnification x40; scale bars represent 200 µm) (C) and Transwell migration assays (original magnification x100; scale bars represent 100 µm) (D) for cell migration in the indicated group. IL13RA2 knockdown showed obvious promotion of migration abilities in MHCC97H and HCCLM3 cells. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, by Student’s t-test. Error bars represent SD. n ≥ 3 independent experiments per condition. 7-AAD, 7-aminoactinomycin D.
the presence of the EGFRvIII, IL13RA2 interacts with EGFRvIII to exert significant influence on cell proliferation. Thus, we presume that different HCC cell lines may mean distinct receptors in the cell membrane, which could bind with IL13RA2 to exhibit different biological functions. Besides, our study neglected the soluble form of IL13RA2, like most of the studies on IL13RA2 in tumors, which may play the opposite role to membrane form. Thus, the exact form of IL13RA2 protein in MHCC97H also could be the reason for the earlier result. Therefore, more about the form and synergistic membrane protein for IL13RA2 in HCC needs to be explored, which may open new viewpoints and provide novel targets for HCC therapeutics.

The latest research showed that EMT is not a binary process but a continuous process [27]; that is, tumor cells will pass through complete epithelial state, transitional hybrid state and complete mesenchymal state. In other words, there are diverse EMT stages in tumor. These subpopulations have different cell plasticity, invasion and metastasis ability. Importantly, hybrid EMT has proved to indicate a higher invasion and metastasis ability [27], and E-cadherin is required for collective cell migration and metastatic colonization [28]. Hence mechanisms of partial EMT urgently need to be explored. Full EMT is regulated by clusters of transcription factors and signaling receptors. McFaline-Figueroa et al.[29] found that distinct transcription factor and receptor gene knockouts could enrich a particular EMT gene profile, such as E-cadherin, leading to a stable intermediate EMT phenotype. In our study, when IL13RA2 was silenced in MHCC97H cells, the epithelial cell marker E-cadherin was down-regulated dramatically, with mesenchymal cell markers N-cadherin and Vimentin up-regulated; whereas in HCCLM3 cells, the mesenchymal cell markers N-cadherin and Vimentin were up-regulated, with retained expression of epithelial cell marker E-cadherin, which is classically characterized as partial or intermediate EMT. As we know, different HCC cell lines in vitro also present genetic heterogeneity, which could enable diverse partial EMT states [30]. In agreement with our study, several related studies have confirmed that over-expression of Slug induces complete EMT in HepG2 cells, with partial EMT in Huh7 cells [31]. In addition, transforming growth factor-β can induce a partial EMT state in PLC/PRF/5 cells, increasing the expression of CD44, without losing epithelial cell adhesion molecule and CD133 expression, whereas in Hep3B cells, transforming growth factor-β treatment provokes a complete EMT [32]. However, the difference in transcript factors and receptors or signaling pathways between HCC cell lines leading to distinct EMT stages is yet to be understood.

ERK signaling pathway is one of the canonical pathways in tumors, playing a pivotal role in EMT [33]. Our study found that HCC cells with IL13RA2 knockdown showed a high level of ERK phosphorylation, indicating that IL13RA2 may suppress EMT in HCC via inhibiting ERK activation. Thus, further investigations are required to reveal the detailed connections between IL13RA2 and the ERK signaling pathway.
Conflict of interest
The authors declare no conflict of interest.

Author contributions
YW conceived the project and reviewed the report. MW and RY collected and analyzed the data. MW interpreted the results and wrote the paper. All authors read and approved the final manuscript.

References
1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424.
2 Llovet JM, Bru C and Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19, 329–338.
3 Niu L, Liu L, Yang S, Ren J, Lai P and Chen GG (2017) New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer 1868, 564–570.
4 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378–390.
5 Andrews AL, Holloway JW, Puddicombe SM, Holgate ST and Davies DE (2002) Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem 277, 46073–46078.
6 Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudaik KE, Scroggins BT, Arron JR, Wynn TA and Citrin DE (2016) IL-13 is a therapeutic target in radiation lung injury. Sci Rep 6, 39714.
7 Mentink-Kane MM and Wynn TA (2004) Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. ImmunoL Rev 202, 191–202.
8 Rosen MJ, Frey MR, Washington MK, Chaturvedi R, Kuhnhein LA, Matta P, Revetta FL, Wilson KT and Polk DB (2011) STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis 17, 2224–2234.
9 Chen Z, Andreev D, Oeser K, Krljmanac B, Hueber A, Kleyer A, Voehringer D, Schett G and Bozec A (2016) Th2 and eosinophil responses suppress inflammatory arthritis. Nat Commun 7, 11596.
10 Kim HJ, Oh GS, Lee JH, Lyu AR, Ji HM, Lee SH, Song J, Park SJ, You YO, Sul JD et al. (2011) Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res 21, 944–956.
11 Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA and Haque SJ (2002) IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 62, 1103–1109.
12 Fujisawa T, Joshi BH and Puri RK (2012) IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 131, 344–356.
13 Fichtner-Feigl S, Strober W, Kawakami K, Puri RK and Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12, 99–106.
14 Tu M, Wange W, Cai L, Zhu P, Gao Z and Zheng W (2016) IL-13 receptor alpha2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol 37, 14701–14709.
15 Tabata Y and Khurana HG (2007) IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep 7, 338–345.
16 Wills-Karp M and Finkelman FD (2008) Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 1, e55.
17 McKenzie AN and Fallon PG (2003) Decoy receptors in the regulation of T helper cell type 2 responses. J Exp Med 197, 675–679.
18 Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK, Pan E, Aliwarga E, Chong ST, Kok C et al. (2017) Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat Commun 8, 1913.
19 Zhao Z, Wang L and Xu W (2015) IL-13Ralpha2 mediates PNR-induced migration and metastasis in E8 Ralpha-negative breast cancer. Oncogene 34, 1596–1607.
20 Bardeas R, Bartolome RA, Fernandez-Acenero MJ, Torres S and Casal JJ (2012) High expression of IL-13 receptor 2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 72, 2780–2790.
21 Fujisawa T, Joshi B, Nakajima A and Puri RK (2009) A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 69, 8678–8685.
22 Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45, W98–W102.
23 Menyhart O, Nagy A and Gyorffy B (2018) Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 5, 181006.
24 Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B and Lesniak MS (2012)
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. *J Biol Chem* **287**, 30215–30227.

Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ and Jensen MC (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. *Cancer Res* **64**, 9160–9166.

Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H *et al*. (2012) Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. *Clin Cancer Res* **18**, 5949–5960.

Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S *et al*. (2018) Identification of the tumour transition states occurring during EMT. *Nature* **556**, 463–468.

Mizukoshi K, Okazawa Y, Haeno H, Koyama Y, Sulidan K, Komiyama H, Saeki H, Ohtsui N, Ito Y, Kojima Y *et al*. (2019) Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state. *Int J Cancer*. [https://doi.org/10.1002/ijc.32672](https://doi.org/10.1002/ijc.32672)

McFaline-Figueroa JL, Hill AJ, Qiu X, Jackson D, Shendure J and Trapnell C (2019) A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. *Nat Genet* **51**, 1389–1398.

Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS *et al*. (2017) Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* **171**, 1611–1624.

Karaosmanoglu O, Banerjee S and Sivas H (2018) Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells. *Cell Oncol (Dordr)* **41**, 439–453.

Malfettone A, Soukupova J, Bertran E, Crosas-Molist E, Lastra R, Fernando J, Koudelkova P, Rani B, Fabra A, Serrano T *et al*. (2017) Transforming growth factor-beta-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma. *Cancer Lett* **392**, 39–50.

Singh M, Yelle N, Venugopal C and Singh SK (2018) EMT: mechanisms and therapeutic implications. *Pharmacol Therapeut* **182**, 80–94.